Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Johnson & johnson symbols : Arct save search
Arcturus Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 9, 2022
Published: 2022-10-26 (Crawled : 22:00) - biospace.com/
JNJ | News | $150.09 0.65% 4.9M
|
Health Technology
|
| O: 0.5%
H: 0.0%
C: 0.0%
ARCT 4 | $28.69 6.02% 140K
|
Health Technology
|
| O: -0.12%
H: 8.05%
C: 2.28%
report therapeutics financial update results
Arcturus Therapeutics to Attend the Following Investor Conferences
Published: 2022-09-27 (Crawled : 23:00) - biospace.com/
JNJ | News | $150.09 0.65% 4.9M
|
Health Technology
|
| O: 0.35%
H: 0.0%
C: 0.0%
ARCT 4 | $28.69 6.02% 140K
|
Health Technology
|
| O: 3.75%
H: 6.06%
C: 4.58%
therapeutics
Arcturus Announces $63.2 Million Award from the U.S. Government to Support Development of Self-amplifying mRNA Vaccine for Rapid Pandemic Influenza Response
Published: 2022-08-31 (Crawled : 22:00) - biospace.com/
JNJ | News | $150.09 0.65% 4.9M
|
Health Technology
|
| O: -0.11%
H: 0.0%
C: 0.0%
ARCT 4 | $28.69 6.02% 140K
|
Health Technology
|
| O: 2.49%
H: 0.83%
C: -2.7%
vaccine rapid mrna response influenza
Arcturus Reports Durability Data Against Omicron Variants, Including BA.5, at Six-Month Timepoint Following Booster with ARCT-154 COVID-19 Vaccine
Published: 2022-08-18 (Crawled : 13:00) - biospace.com/
JNJ | News | $150.09 0.65% 4.9M
|
Health Technology
|
| O: 0.85%
H: 0.0%
C: 0.0%
ARCT 4 | $28.69 6.02% 140K
|
Health Technology
|
| O: 0.0%
H: 0.26%
C: -8.59%
arct-154 covid-19 vaccine
Arcturus Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 9, 2022
Published: 2022-08-01 (Crawled : 21:00) - biospace.com/
JNJ | News | $150.09 0.65% 4.9M
|
Health Technology
|
| O: 0.22%
H: 0.0%
C: 0.0%
ARCT 4 | $28.69 6.02% 140K
|
Health Technology
|
| O: -2.17%
H: 7.16%
C: 1.75%
report therapeutics update results
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - June 22, 2022
Published: 2022-06-22 (Crawled : 09:00) - biospace.com/
TAK | News | $13.41 0.37% 1M
|
Health Technology
|
| O: 1.28%
H: 0.0%
C: 0.0%
JNJ | News | $150.09 0.65% 4.9M
|
Health Technology
|
| O: 1.36%
H: 0.0%
C: 0.0%
ARCT 4 | $28.69 6.02% 140K
|
Health Technology
|
| O: -0.64%
H: 14.95%
C: 10.14%
nasdaq grant therapeutics employment compensation
Arcturus Therapeutics Announces First Quarter 2022 Financial Update and Pipeline Progress
Published: 2022-05-09 (Crawled : 21:00) - biospace.com/
TAK | News | $13.41 0.37% 1M
|
Health Technology
|
| O: -0.69%
H: 0.28%
C: -1.1%
JNJ | News | $150.09 0.65% 4.9M
|
Health Technology
|
| O: 0.15%
H: 0.0%
C: 0.0%
ARCT 4 | $28.69 6.02% 140K
|
Health Technology
|
| O: -2.88%
H: 2.34%
C: -8.64%
therapeutics
Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial
Published: 2022-05-05 (Crawled : 13:00) - biospace.com/
TAK | News | $13.41 0.37% 1M
|
Health Technology
|
| O: 0.55%
H: 0.0%
C: -1.16%
JNJ | News | $150.09 0.65% 4.9M
|
Health Technology
|
| O: 0.72%
H: 0.0%
C: 0.0%
ARCT 4 | $28.69 6.02% 140K
|
Health Technology
|
| O: 6.93%
H: 1.13%
C: -8.47%
arct-154 trial results
Arcturus Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on May 9, 2022
Published: 2022-04-27 (Crawled : 12:20) - biospace.com/
TAK | News | $13.41 0.37% 1M
|
Health Technology
|
| O: -0.76%
H: 0.66%
C: 0.28%
JNJ | News | $150.09 0.65% 4.9M
|
Health Technology
|
| O: -0.77%
H: 0.0%
C: 0.0%
ARCT 4 | $28.69 6.02% 140K
|
Health Technology
|
| O: -6.84%
H: 1.52%
C: -3.65%
report therapeutics results
Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study
Published: 2022-04-20 (Crawled : 12:00) - biospace.com/
TAK | News | $13.41 0.37% 1M
|
Health Technology
|
| O: 1.17%
H: 0.68%
C: 0.27%
JNJ | News | $150.09 0.65% 4.9M
|
Health Technology
|
| O: 1.06%
H: 1.14%
C: 0.91%
ARCT 4 | $28.69 6.02% 140K
|
Health Technology
|
| O: -20.04%
H: 28.04%
C: 21.44%
covid-19 arct-154 vaccine mrna phase 3
Arcturus Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit
Published: 2022-03-25 (Crawled : 14:20) - biospace.com/
TAK | News | $13.41 0.37% 1M
|
Health Technology
|
| O: -0.53%
H: 0.57%
C: 0.34%
JNJ | News | $150.09 0.65% 4.9M
|
Health Technology
|
| O: 0.65%
H: 0.0%
C: 0.0%
ARCT 4 | $28.69 6.02% 140K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -3.21%
rare therapeutics disease
Arcturus Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Update and Pipeline Progress
Published: 2022-02-28 (Crawled : 22:00) - biospace.com/
TAK | News | $13.41 0.37% 1M
|
Health Technology
|
| O: 0.54%
H: 1.66%
C: 1.13%
JNJ | News | $150.09 0.65% 4.9M
|
Health Technology
|
| O: 1.79%
H: 0.0%
C: 0.0%
ARCT 4 | $28.69 6.02% 140K
|
Health Technology
|
| O: -0.93%
H: 3.16%
C: 2.35%
ces therapeutics
Arcturus Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022
Published: 2022-02-16 (Crawled : 14:00) - biospace.com/
TAK | News | $13.41 0.37% 1M
|
Health Technology
|
| O: -0.07%
H: 0.59%
C: 0.53%
JNJ | News | $150.09 0.65% 4.9M
|
Health Technology
|
| O: -0.49%
H: 0.81%
C: 0.43%
ARCT 4 | $28.69 6.02% 140K
|
Health Technology
|
| O: -2.58%
H: 1.98%
C: 1.07%
financial results therapeutics report results
Arcturus Therapeutics Reports New Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Clinical Trial
Published: 2022-01-25 (Crawled : 13:30) - biospace.com/
TAK | News | $13.41 0.37% 1M
|
Health Technology
|
| O: -0.76%
H: 2.02%
C: 1.04%
JNJ | News | $150.09 0.65% 4.9M
|
Health Technology
|
| O: -0.37%
H: 3.73%
C: 3.25%
ARCT 4 | $28.69 6.02% 140K
|
Health Technology
|
| O: 0.24%
H: 4.13%
C: 1.44%
arct-154 trial therapeutics response sars-cov-2 report pons antibody
Arcturus Therapeutics Updates Data from ARCT-154 and ARCT-165 Booster Clinical Trial Demonstrating Robust Neutralizing Antibody Responses to SARS-CoV-2 and Several Variants
Published: 2022-01-24 (Crawled : 14:00) - biospace.com/
TAK | News | $13.41 0.37% 1M
|
Health Technology
|
| O: 1.18%
H: 0.34%
C: -0.69%
JNJ | News | $150.09 0.65% 4.9M
|
Health Technology
|
| O: -1.19%
H: 0.1%
C: -0.63%
ARCT 4 | $28.69 6.02% 140K
|
Health Technology
|
| O: -2.85%
H: 3.12%
C: 2.09%
arct-154 trial therapeutics response sars-cov-2 pons antibody
Arcturus Therapeutics Reports New Data and Provides Additional Updates from ARCT-154 and ARCT-165 Clinical Trials
Published: 2021-12-16 (Crawled : 14:00) - biospace.com/
TAK | News | $13.41 0.37% 1M
|
Health Technology
|
| O: 1.18%
H: 0.0%
C: 0.0%
JNJ | News | $150.09 0.65% 4.9M
|
Health Technology
|
| O: 0.59%
H: 0.0%
C: 0.0%
ARCT 4 | $28.69 6.02% 140K
|
Health Technology
|
| O: 10.59%
H: 17.58%
C: 13.16%
arct-154 als trials trial therapeutics clinical trials
Arcturus Therapeutics Appoints Jing Marantz, M.D., Ph.D., M.B.A. to its Board of Directors
Published: 2021-12-13 (Crawled : 13:30) - biospace.com/
TAK | News | $13.41 0.37% 1M
|
Health Technology
|
| O: -0.59%
H: 0.0%
C: 0.0%
JNJ | News | $150.09 0.65% 4.9M
|
Health Technology
|
| O: -0.41%
H: 0.0%
C: 0.0%
KRYS | News | $162.985 3.65% 99K
|
Health Technology
|
| O: -1.65%
H: 0.0%
C: 0.0%
ARCT 4 | $28.69 6.02% 140K
|
Health Technology
|
| O: -6.92%
H: 0.0%
C: 0.0%
therapeutics
Arcturus Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference
Published: 2021-11-22 (Crawled : 13:30) - biospace.com/
TAK | News | $13.41 0.37% 1M
|
Health Technology
|
| O: -1.03%
H: 0.14%
C: -0.65%
JNJ | News | $150.09 0.65% 4.9M
|
Health Technology
|
| O: -1.22%
H: 1.0%
C: -0.83%
ARCT 4 | $28.69 6.02% 140K
|
Health Technology
|
| O: -2.88%
H: 1.38%
C: -1.52%
conference therapeutics
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Nov 19, 2021
Published: 2021-11-19 (Crawled : 10:00) - biospace.com/
TAK | News | $13.41 0.37% 1M
|
Health Technology
|
| O: -0.25%
H: 0.0%
C: 0.0%
JNJ | News | $150.09 0.65% 4.9M
|
Health Technology
|
| O: 0.38%
H: 0.0%
C: 0.0%
ARCT 4 | $28.69 6.02% 140K
|
Health Technology
|
| O: -1.26%
H: 0.0%
C: 0.0%
granted grant
Arcturus Therapeutics Announces Leadership Appointments
Published: 2021-10-21 (Crawled : 13:00) - biospace.com/
TAK | News | $13.41 0.37% 1M
|
Health Technology
|
| O: -0.28%
H: 0.07%
C: -0.57%
JNJ | News | $150.09 0.65% 4.9M
|
Health Technology
|
| O: 0.32%
H: 0.05%
C: -0.55%
ARCT 4 | $28.69 6.02% 140K
|
Health Technology
|
| O: -0.23%
H: 3.07%
C: 1.97%
therapeutics
Gainers vs Losers
| 87% | 13% |
Top 10 Gainers
MTTR | News M | $4.56 162.07% 21M
|
AGBA | $2.74 119.2% 52M
|
Finance
CZOO | $9.07 81.76% 22M
|
EDBL | News | $6.56 74.47% 1.8M
|
MTC | $2.21 41.67% 5.6M
|
Technology Services
OPRT | News | $3.12 38.67% 11M
|
Finance
PALI | $6.59 33.67% 23M
|
Manufacturing
VNRX | $0.7945 32.42% 3.1M
|
Health Technology
MLEC | $1.81 29.29% 2.8M
|
n/a
BTCM | $3.45 27.78% 640K
|
Arts, Entertainment, and Recrea...
Your saved searches
Save your searches and get alerts when important news are released.